Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
Authors
Keywords
-
Journal
GENE THERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-22
DOI
10.1038/s41434-021-00246-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients
- (2020) Maria-Luisa Schubert et al. BLOOD
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors
- (2020) Katharina Reinhard et al. SCIENCE
- High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
- (2020) Stephan Müller et al. Frontiers in Immunology
- Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
- (2020) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).
- (2020) Joerg Krueger et al. JOURNAL OF CLINICAL ONCOLOGY
- Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
- (2020) Frederick Lundry Locke et al. JOURNAL OF CLINICAL ONCOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B‐Cell Lymphoma
- (2020) Irene Papadouli et al. ONCOLOGIST
- CAR T cells: Living HIV drugs
- (2020) Haideh Namdari et al. REVIEWS IN MEDICAL VIROLOGY
- The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
- (2020) Andriy Zhylko et al. Cancers
- Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
- (2020) Arezoo Jamali et al. Frontiers in Immunology
- Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
- (2019) Nirav N. Shah et al. Frontiers in Oncology
- CAR-T efficacy: is conditioning the key?
- (2019) Sattva S. Neelapu BLOOD
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- EU Regulatory Pathways for ATMPs: Standard, Accelerated and Adaptive Pathways to Marketing Authorisation
- (2019) Giulia Detela et al. Molecular Therapy-Methods & Clinical Development
- Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors
- (2019) Ashwini Balakrishnan et al. CLINICAL CANCER RESEARCH
- Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion
- (2019) Andrew J. Freeman et al. Cell Reports
- CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy
- (2019) Michael C. Burger et al. Frontiers in Immunology
- Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
- (2018) Fenlu Zhu et al. CYTOTHERAPY
- Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma
- (2018) Michael D Jain et al. Therapeutics and Clinical Risk Management
- Tumor gene signature associated with neurotoxicity in R/R B-ALL patients treated with JCAR015, a CD19-directed CAR T cell product.
- (2018) N. Eric Olson et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
- (2018) Shih-Feng Cho et al. Frontiers in Immunology
- Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors
- (2018) Yong Gu Lee et al. CANCER RESEARCH
- NK cell-based immunotherapy for cancer
- (2017) Fang Fang et al. SEMINARS IN IMMUNOLOGY
- Shaping of Natural Killer Cell Antitumor Activity by Ex Vivo Cultivation
- (2017) Markus Granzin et al. Frontiers in Immunology
- Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
- (2017) Federico Simonetta et al. Frontiers in Immunology
- Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
- (2017) Congcong Zhang et al. Frontiers in Immunology
- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells
- (2016) Hans Klingemann et al. Frontiers in Immunology
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
- (2015) Congcong Zhang et al. JNCI-Journal of the National Cancer Institute
- A BCMA-specific CAR T cell produced with clinically scalable lentiviral and T cell manufacturing processes has potent anti-multiple myeloma activity
- (2015) Tracy E Garrett et al. Journal for ImmunoTherapy of Cancer
- Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells
- (2015) Max Schlaak et al. Oncotarget
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells
- (2013) C Arndt et al. LEUKEMIA
- Interleukin 2 in Cancer Therapy
- (2012) G. K. Antony et al. CURRENT MEDICINAL CHEMISTRY
- Natural killer cell lines in tumor immunotherapy
- (2012) Min Cheng et al. Frontiers of Medicine
- Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
- (2010) L. Moretta et al. BLOOD
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. JOURNAL OF CLINICAL ONCOLOGY
- The future of CD20 monoclonal antibody therapy in B-cell malignancies
- (2010) Myron S. Czuczman et al. LEUKEMIA & LYMPHOMA
- Generation of donor natural killer cells from CD34+ progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study
- (2009) S R Yoon et al. BONE MARROW TRANSPLANTATION
- CD33 Detection by Immunohistochemistry in Paraffin-Embedded Tissues
- (2008) James D. Hoyer et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Natural killer cell–directed therapies: moving from unexpected results to successful strategies
- (2008) Magali Terme et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started